Редактирование: IDUA

Alpha-L-iduronidase precursor (EC 3.2.1.76)

==Publications==

{{medline-entry
|title=Increased longevity and metabolic correction following syngeneic BMT in a murine model of mucopolysaccharidosis type I.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/22179554
|abstract=Mucopolysaccharidosis type I (MPS I) is an autosomal recessive inherited disease caused by deficiency of the glycosidase α-L-iduronidase ([[IDUA]]). Deficiency of [[IDUA]] leads to lysosomal accumulation of glycosaminoglycans (GAG) heparan and dermatan sulfate and associated multi-systemic disease, the most severe form of which is known as Hurler syndrome. Since 1981, the treatment of Hurler patients has often included allogeneic BMT from a matched donor. However, mouse models of the disease were not developed until 1997. To further characterize the MPS-I mouse model and to study the effectiveness of BMT in these animals, we engrafted a cohort (n=33) of 4-8-week-old Idua(-/-) animals with high levels (88.4±10.3%) of wild-type donor marrow. Engrafted animals displayed an increased lifespan, preserved cardiac function, partially restored [[IDUA]] activity in peripheral organs and decreased GAG accumulation in both peripheral organs and in the brain. However, levels of GAG and GM3 ganglioside in the brain remained elevated in comparison to unaffected animals. As these results are similar to those observed in Hurler patients following BMT, this murine-transplantation model can be used to evaluate the effects of novel, more effective methods of delivering [[IDUA]] to the brain as an adjunct to BMT.
|mesh-terms=* Animals
* Bone Marrow Transplantation
* Cohort Studies
* Disease Models, Animal
* Iduronidase
* Longevity
* Male
* Mice
* Mice, Inbred C57BL
* Mice, Transgenic
* Mucopolysaccharidosis I

|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465813
}}
{{medline-entry
|title=Gene therapy of the brain in the dog model of Hurler's syndrome.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/16718701
|abstract=A defect of the lysosomal enzyme alpha-L-iduronidase ([[IDUA]]) interrupts the degradation of glycosaminoglycans in mucopolysaccharidosis type I, causing severe neurological manifestations in children with Hurler's syndrome. Delivery of the missing enzyme through stereotactic injection of adeno-associated virus vectors coding for [[IDUA]] prevents neuropathology in affected mice. We examined the efficacy and the safety of this approach in enzyme-deficient dogs. Because deficient dogs raise antibodies against [[IDUA]] in response to infusion, intracerebral vector injections were combined with an immunosuppressive regimen. Treatment was tolerated well. We observed broad dispersion of vector genomes in the brain of efficiently immunosuppressed dogs. The delivery of [[IDUA]] to large areas, which could encompass the entire brain, prevented glycosaminoglycan and secondary ganglioside accumulations. This condition was associated with drastic reduction of neuropathology throughout the encephalon. In contrast, vector injection combined with partial immunosuppression was associated with subacute encephalitis, production of antibodies against [[IDUA]] in brain tissues, and elimination of genetically modified cells. Gene therapy directed to the entire brain is feasible and may be beneficial to children with Hurler's syndrome. The possibility of subacute encephalitis emphasizes the importance of preventing immune response against [[IDUA]], a problem that needs to be considered in similar therapies for other genetic defects.
|mesh-terms=* Adenoviridae
* Aging
* Animals
* Autoantibodies
* Body Weight
* Brain
* Dogs
* Female
* Gangliosides
* Genetic Therapy
* Genetic Vectors
* Glycosaminoglycans
* Iduronidase
* Male
* Mucopolysaccharidosis I
* Reverse Transcriptase Polymerase Chain Reaction
* Stereotaxic Techniques

|full-text-url=https://sci-hub.do/10.1002/ana.20870
}}
{{medline-entry
|title=Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/15851016
|abstract=Mucopolysaccharidosis type I (MPS I) is a lysosomal glycosaminoglycan (GAG) storage disorder caused by deficiency of alpha-l-iduronidase ([[IDUA]]). In this study, we evaluated the potential to perform gene therapy for MPS I by direct in vivo injection of a lentiviral vector, using an [[IDUA]] gene knockout murine model. We compared the efficacy in newborn versus young adult MPS I mice of a single intravenous injection of the lentiviral vector. The extent of transduction was dose-dependent, with the liver receiving the highest level of vector, but other somatic organs reaching almost the same level. The phenotypic manifestations of disease were partially improved in the mice treated as young adults, but were nearly normalized at every end-point measured in the mice treated as neonates. In the neonatally treated mice, the expressed [[IDUA]] activity resulted in decreased GAG storage, prevention of skeletal abnormalities, a more normal gross appearance, and improved survival. Most strikingly, significant levels of [[IDUA]] enzyme were produced in the brain of mice treated as neonates, with transduction of neurons at high levels. The sustained expression of enzymatically active [[IDUA]] in multiple organs had a significant beneficial effect on the phenotypic abnormalities of MPS I, which may be translated to clinical gene therapy of patients with Hurler disease.
|mesh-terms=* Aging
* Animals
* Animals, Newborn
* Bone and Bones
* Cell Line, Tumor
* Central Nervous System
* DNA, Complementary
* Gene Expression
* Genetic Therapy
* Genetic Vectors
* Glycosaminoglycans
* Humans
* Iduronidase
* Injections, Intravenous
* Lentivirus
* Lysosomes
* Mice
* Mice, Knockout
* Mucopolysaccharidosis I
* Neurons
* Sulfur
* Survival Rate

|full-text-url=https://sci-hub.do/10.1016/j.ymthe.2004.10.006
}}